AGPU AGPU Drug Discovery Services — Net Income Loss Excluding Discontinued Operations
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AGPU in its filing.
Tagged under the XBRL concept agpu:NetIncomeLossExcludingDiscontinuedOperations.
The official record: AGPU’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about AGPU's drug discovery services — net income loss excluding discontinued operations.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AGPU's drug discovery services — net income loss excluding discontinued operations?
- AGPU (AGPU) reported drug discovery services — net income loss excluding discontinued operations of -$978.38K in Q1 2026.
- How has AGPU's drug discovery services — net income loss excluding discontinued operations changed year-over-year?
- AGPU's drug discovery services — net income loss excluding discontinued operations decreased by 12.8% year-over-year, from -$867.41K to -$978.38K.
- What does drug discovery services — net income loss excluding discontinued operations mean?
- Indicates the net financial result of the Drug Discovery Services segment, excluding any impact from discontinued business units. This provides a focused view of the segment's bottom-line contribution to the company's overall financial health. It is used to assess the segment's long-term viability and profitability after all associated costs.